First-line Therapy for Renal Cell Carcinoma

Navigating Treatment Complexities in First- and Second-Line Therapies for mRCCПодробнее

Immune Checkpoint Inhibitors In Renal Cell CarcinomaПодробнее

Dr Singer on the Efficacy of IO/TKI Doublets in Advanced RCCПодробнее

ETER100: benmelstobart and anlotinib in advanced renal cell carcinomaПодробнее

Immunotherapy in Patients with Localized Renal Cell Carcinoma: The PROSPER Trial and BeyondПодробнее

AUA2022: Surgical & Medical Management of High-Risk Renal Cell CarcinomaПодробнее

Pharmaceutical Approaches to Renal Cell Carcinoma Open ForumПодробнее

5-year follow-up of EV and pembrolizumab for la/mUC in the EV-103 trialПодробнее

Clinical Management of VHL Tumors - Systemic Agents for VHL | Medical Symposium 2024Подробнее

Front-line Therapy in Papillary Renal Cancer: Uromigos Live 2024Подробнее

Dr Liao on Selecting Between First-Line Monotherapy and Combination Approaches in HCCПодробнее

Investigator Perspectives on Available Research and Challenging Questions in Renal Cell Carcinoma:Подробнее

Dr Saliby on the Correlation Between Intermediate End Points and OS in Metastatic RCCПодробнее

KCRS24 - Biotech Showcase on Emerging Therapies for Kidney Cancer | KidneyCANПодробнее

[Interview with Author, September 2024] BMI and outcomes in mRCC on first-line ICIПодробнее

Advanced renal cell carcinoma: Managing long term durable responseПодробнее

KCRS24 Session Five: Clinical and Scientific Updates in Kidney Cancer | KidneyCANПодробнее

04_08 Metastatic Renal Cell CarcinomaПодробнее

Emerging First-Line ICI Combination Regimens in Patients With Unresectable HCCПодробнее

Investigator Perspectives on Available Research and Challenging Questions in Renal Cell Carcinoma...Подробнее